Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Lei Feng et al.|Journal of Hematology & Oncology|2023Cited by 52
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Elyse I. Harris et al.|Blood Advances|2022Cited by 50
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Alexey V. Danilov, Andy Kaempf et al.|Blood Advances|2023Cited by 49
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L. Crombie, Gary Simmons, Loretta J. Nastoupil et al.|Blood Advances|2021Cited by 36
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell LymphomaAlex F. Herrera, Matthew J. Matasar, Lu Chen et al.|Blood|2022Cited by 18